Radiation therapy for breast cancer can injure the lung tissue that sits just behind the chest wall, and the damage generally takes one of two forms: an early inflammatory reaction called radiation pneumonitis, or a slower scarring process called pulmonary fibrosis. Symptomatic pneumonitis affects a relatively small fraction of breast cancer patients who receive radiation, with reported rates often landing somewhere around one to fifteen percent depending on the treatment setup and what other therapies are given alongside it. Still, even patients who never develop obvious symptoms can show measurable changes in lung function that persist for years. The good news is that modern treatment planning has gotten considerably better at limiting lung exposure, and the tools available today bear little resemblance to the crude field designs of decades past.
What Actually Happens to the Lung
When radiation beams pass through lung tissue on their way to the breast or chest wall, the energy is strong enough to break DNA strands in the cells it hits and to generate reactive oxygen species from water molecules in the tissue. Those reactive molecules go on to damage additional cells and trigger an immediate burst of inflammatory signals, sometimes called a cytokine storm, within the first 24 hours after treatment.1PubMed Central. Cytokines and radiation-induced pulmonary injuries Epithelial and endothelial cells in the lung can begin dying through programmed cell death within hours of exposure. Most DNA damage gets repaired, but errors in that repair accumulate over many treatment sessions and set the stage for longer-term consequences.
If the inflammation stays active or the repair process goes sideways, fibroblasts in the lung start transforming into myofibroblasts, cells that produce stiff, scar-like connective tissue. Research has identified a feed-forward loop where radiation increases an enzyme involved in lactate production, and that lactate in turn activates a key growth factor (TGF-β) that drives even more scarring.2PubMed Central. Ionizing radiation induces myofibroblast differentiation via lactate dehydrogenase The end result, when it progresses, is a buildup of extracellular matrix deposits in the lung, effectively replacing flexible, air-exchanging tissue with dense scar tissue.3PubMed Central. The Cellular and Molecular Mechanism of Radiation-Induced Lung Injury
Pneumonitis Versus Fibrosis and How They Feel
Radiation pneumonitis is the acute phase. It usually shows up one to six months after radiation ends. The hallmark symptoms are a dry, nonproductive cough, shortness of breath, low-grade fever, and sometimes chest discomfort. In one older study of breast cancer patients who developed symptomatic pneumonitis, cough appeared in about 88 percent, fever in roughly half, and shortness of breath in about a third.4International Journal of Radiation Oncology*Biology*Physics. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy These symptoms can mimic a respiratory infection, so doctors typically confirm the diagnosis by looking for ground-glass opacities or areas of consolidation on a CT scan that line up with the radiation field.
The chronic phase, radiation fibrosis, develops months to years later and shows up on imaging as traction bronchiectasis, volume loss, and scarring in the irradiated region.5PubMed. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis Fibrosis is harder to reverse than pneumonitis. While acute pneumonitis usually responds well to corticosteroids, fibrosis represents permanent architectural change. Identifying who will progress from early inflammation to lasting fibrosis remains one of the harder problems in radiation oncology.6PubMed Central. Radiation-Induced Lung Injury: Assessment and Management
Many patients never notice symptoms at all but still show changes on imaging. In clinical studies that perform routine CT scans after breast radiation, radiographic signs of pneumonitis without any clinical symptoms are far more common than the symptomatic version. These asymptomatic findings are graded differently and generally don’t require treatment, but they signal that the lung tissue has been affected.
How Much Lung Gets Irradiated Matters Most
The single strongest predictor of lung complications is how much lung tissue receives a meaningful radiation dose. Dosimetric studies consistently point to the volume of lung receiving 20 Gy or more, abbreviated V20, as a critical threshold. One study of various breast radiation techniques found a clear correlation between increasing V20 values and the likelihood of both clinical and radiographic lung side effects.7PubMed. Pulmonary complications following different radiotherapy techniques for breast cancer, and the association to irradiated lung volume and dose Another study showed that the volume of lung receiving more than 13 Gy independently predicted radiological changes on CT.8PubMed Central. Reduction of radiation pneumonitis by V20-constraints in breast cancer
A prospective study that tracked breast cancer patients after radiation found that about one in ten developed pneumonitis, and that cutoff values for the ipsilateral lung’s V5, V10, V20, and mean lung dose could meaningfully predict who would be affected. The V20 cutoff in that study was around 23 percent, and the mean lung dose cutoff was about 12 Gy.9SpringerLink / Clin Transl Oncol. Radiation pneumonitis in relation to pulmonary function, dosimetric factors, TGFβ1 expression, and quality of life in breast cancer patients receiving post-operative radiotherapy These numbers are the reason treatment planners work hard to keep the V20 below established limits, often trying to stay under 30 to 35 percent for the ipsilateral lung.
When the Treatment Field Grows
Breast-only radiation, where beams target just the breast or chest wall, naturally exposes less lung than regional treatments that also include lymph node areas. When the internal mammary nodes, which sit along the edge of the breastbone, need to be irradiated, the dose to the underlying lung increases. One recent study of early breast cancer patients found that adding internal mammary node irradiation raised the mean ipsilateral lung dose by about 2.7 Gy, and that lung dose constraints were the primary reason desired coverage could not always be achieved.10PubMed Central. Internal mammary node irradiation in early breast cancer – target coverage and implications on dose to organs at risk Despite that increase, the rate of symptomatic pneumonitis in that cohort was under one percent, suggesting that modern planning can keep things in check even with broader treatment fields.
Post-mastectomy radiation, which covers the chest wall and often includes regional nodes, has historically carried higher lung doses than breast-conserving approaches. The larger the target area, the more lung tissue sits in the beam path. This is one reason why treatment planning for locoregional radiation receives such careful attention, and why techniques like deep inspiration breath hold become especially valuable for these patients.
Deep Inspiration Breath Hold and Other Dose-Sparing Techniques
Deep inspiration breath hold, or DIBH, is one of the most effective and widely available tools for reducing lung (and heart) dose. The concept is straightforward: when you take a deep breath and hold it, your lungs inflate and the chest wall moves away from the heart, while the expanded lung volume means that a smaller percentage of the total lung sits inside the treatment field. One study showed that DIBH reduced the average V20 of the ipsilateral lung from about 44.5 percent to 32.7 percent, bringing most patients into compliance with national guidelines that none of them met during normal breathing.11PubMed. Radiation during deep inspiration allows loco-regional treatment of left breast and axillary-, supraclavicular- and internal mammary lymph nodes without compromising target coverage or dose restrictions to organs at risk For patients receiving internal mammary node irradiation, DIBH reduced the V20 of the left lung from roughly 38 percent to about 32 percent.12PubMed. Deep inspiration breathhold for left-sided breast cancer patients with unfavorable cardiac anatomy requiring internal mammary nodal irradiation
Beyond DIBH, the choice of radiation technique itself affects how dose spreads through the lung. Intensity-modulated radiation therapy (IMRT) can sculpt the dose more precisely than older three-dimensional conformal approaches (3D-CRT). Comparisons between the two consistently show that IMRT reduces the volume of lung receiving high doses. In one dosimetric study of post-mastectomy chest wall irradiation, IMRT cut the V20 from about 30 percent to about 22 percent and the mean lung dose from roughly 14 Gy to about 11 Gy.13PubMed Central. Dosimetric comparison of IMRT versus 3DCRT for post-mastectomy chest wall irradiation However, there is a trade-off: IMRT tends to bathe a larger volume of lung in low doses. 3D-CRT actually comes out ahead in the V5 metric, the volume receiving at least 5 Gy.14PubMed Central. Dosimetric Comparison of Three-Dimensional Conformal Radiotherapy (3D-CRT) and Intensity Modulated Radiotherapy Techniques (IMRT) with Radiotherapy Dose Simulations for Left-Sided Mastectomy Patients Whether that low-dose bath matters clinically over the long term is still debated, but it is something planners weigh when choosing a technique.
The Low-Dose Bath and Secondary Cancer Risk
The spread of low-dose radiation with IMRT and volumetric modulated arc therapy (VMAT) raises a separate concern: secondary cancer risk. One modeling study calculated the lifetime attributable risk of developing a radiation-induced cancer in the ipsilateral lung. For 3D-CRT, that risk was estimated at about 0.76 per 100,000 people. For IMRT it jumped to about 10.6, and for VMAT it was roughly 12.3.15Journal of Radiological Protection. Radiotherapy-induced secondary cancer risk for breast cancer: 3D conformal therapy versus IMRT versus VMAT Those absolute numbers are small, but the relative difference is striking and underscores why the fanciest technology is not always the best choice for every patient. For someone with a straightforward anatomy who can be treated well with simpler beams and DIBH, 3D-CRT may actually be the smarter plan from a long-term safety perspective.
Proton Therapy as an Alternative
Proton beams deposit most of their energy at a specific depth and then stop, which in theory makes them ideal for sparing structures behind the target. Dosimetric comparisons bear this out. In one study of bilateral breast cancer patients, protons cut the median V20 of both lungs from about 19 percent with photons to about 7 percent.16International Journal of Particle Therapy. Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer Another study comparing photon and proton plans for breast cancer confirmed significantly lower V5 and V20 values with protons.17International Journal of Particle Therapy. Effects on Lung Tissue After Breast Cancer Radiation: Comparing Photon and Proton Therapies Proton therapy remains expensive and not widely available, so it tends to be reserved for patients whose anatomy makes it difficult to meet dose constraints with standard photon techniques, or for patients who need comprehensive nodal irradiation where the potential dose savings are greatest.
Chemotherapy Combinations That Raise Risk
Radiation alone is not the only variable. Certain chemotherapy drugs delivered alongside or shortly before radiation can amplify lung toxicity. The most well-documented example involves paclitaxel. In a retrospective study, breast cancer patients who received paclitaxel-containing chemotherapy had a crude pneumonitis rate of about 15 percent, compared with roughly 1 percent in patients who received chemotherapy without paclitaxel.18PubMed. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel That is a dramatic difference and has led to careful scheduling of taxane-based chemotherapy and radiation to minimize overlap.
A systematic analysis of radiation pneumonitis risk in breast cancer patients examined the role of various co-treatments, including endocrine therapy and targeted agents. The interplay between systemic therapy and radiation is complicated enough that treatment teams now routinely consider it during planning.19PubMed Central. Systematic risk analysis of radiation pneumonitis in breast cancer: role of cotreatment with chemo-, endocrine, and targeted therapy If you are receiving or recently completed chemotherapy, your radiation oncologist should factor that into the acceptable dose limits for your lung.
Other Risk Factors Worth Knowing
Pre-existing lung disease is an intuitive risk factor, though the data are more nuanced than you might expect. A prospective study of breast cancer patients found that a history of pneumonia was a significant predictor of developing radiation pneumonitis afterward. Somewhat counterintuitively, patients with a smoking history did not show a significantly higher rate in that particular study, though the sample was small and the trend was not definitive. Patients with chronic obstructive lung disease also did not appear to be at dramatically elevated risk in that cohort.20PubMed Central. Occurrence of pneumonitis following radiotherapy of breast cancer – A prospective study
Blood levels of TGF-β1, a growth factor central to the fibrotic cascade, have been investigated as a potential biomarker. Higher post-radiation TGF-β1 levels have been found in patients who develop pneumonitis, though specific genetic variants in the TGF-β1 gene did not differ between patients who developed pneumonitis and those who did not.9SpringerLink / Clin Transl Oncol. Radiation pneumonitis in relation to pulmonary function, dosimetric factors, TGFβ1 expression, and quality of life in breast cancer patients receiving post-operative radiotherapy A reliable, widely validated blood test to predict who will get pneumonitis before it happens does not yet exist, but the search is active.
What Happens to Lung Function Over the Long Term
Even without symptomatic pneumonitis, radiation to the breast area tends to chip away at measurable lung function. A 2025 meta-analysis that pooled data from multiple studies found clinically meaningful drops in several lung function metrics. Forced expiratory volume (a measure of how much air you can blow out in one second) fell by about 8 percent of predicted value at one month and was still down around 5 percent at one year. Forced vital capacity (total air exhaled forcefully) dropped in a similar range. Diffusion capacity, which reflects how efficiently the lungs transfer oxygen into the blood, declined by roughly 8 percent at one month and nearly 7 percent at 12 months.21PubMed. Assessing lung function in women treated for breast cancer with radiotherapy. A comprehensive systematic review and meta-analysis
Longer follow-up paints a mixed picture. A study tracking patients out to 12 years found that most lung function measures declined within three months and stayed low at long-term follow-up, though diffusion capacity showed some recovery over time. Patients who also received chemotherapy had larger declines in vital capacity and forced expiratory volume than those who received radiation alone.22International Journal of Radiation Oncology, Biology, Physics. Pulmonary Function and Lung Fibrosis up to 12 Years After Breast Cancer Radiotherapy Another study with roughly 11 years of follow-up found median reductions in vital capacity of about 15 percent and in diffusion capacity that left it at about 86 percent of predicted, indicating chronic impairment from a combination of radiation and chemotherapy effects.23PubMed. Long-term functional and radiological pulmonary changes after radiation therapy for breast cancer
For most patients, these declines stay subclinical, meaning they show up on a breathing test but don’t noticeably limit daily activities. But for someone who already has compromised lungs from smoking, asthma, or other conditions, that additional hit can push them past a threshold where they feel it. This is one reason your baseline lung health matters in treatment planning.
Hypofractionation and Whether It Changes Lung Risk
Hypofractionated radiation, which delivers fewer but slightly larger daily doses over about three weeks instead of the traditional five, has become standard for many breast cancer patients. A reasonable concern is whether bigger daily doses to the lung might be worse. The answer, based on current evidence, is reassuring. A meta-analysis comparing hypofractionated and conventionally fractionated post-mastectomy radiation found no significant difference in acute lung toxicity between the two schedules.24PubMed Central. Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review A single-institution study evaluating lung changes with high-resolution CT and pulmonary function tests after whole-breast radiation similarly found minimal lung toxicity in both the hypofractionated and conventional arms.25PubMed Central. Radiation induced pneumonitis following whole breast radiotherapy treatment in early breast cancer patients treated with breast conserving surgery: a single institution study
Treating Radiation Pneumonitis When It Happens
When symptomatic radiation pneumonitis does develop, the standard treatment is oral corticosteroids. Typical starting doses range from 40 to 60 mg of prednisone daily, followed by a slow taper that varies from patient to patient.26PubMed. Case series of radiation pneumonitis in breast cancer Most patients respond well, and the symptoms resolve over weeks. However, tapering too quickly can cause a rebound, and some patients need to restart steroids when symptoms flare. In the same case series, two patients had recurrence of symptoms after the initial course and required retreatment.
The radiographic changes from the acute phase, those ground-glass opacities, typically resolve within about 1 to 12 months in most cases.4International Journal of Radiation Oncology*Biology*Physics. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy What can remain indefinitely is a band of scarring visible on CT that corresponds to the radiation field. This chronic scarring usually does not progress or cause problems, but it can occasionally be mistaken for disease recurrence on imaging, which is worth knowing so you and your doctors don’t panic at a follow-up scan.
Predictive Tools and Emerging Research
Researchers are working on ways to predict radiation pneumonitis earlier and more accurately. One promising approach uses radiomic features extracted from CT scans, essentially computer-derived texture patterns invisible to the human eye, combined with machine learning to flag patients likely to develop pneumonitis. Early results suggest that texture-oriented features can enhance model accuracy enough to be clinically useful for guiding treatment adjustments.27PubMed Central. Personalized diagnosis of radiation pneumonitis in breast cancer patients based on radiomics
On the treatment side, there is interest in drugs that could prevent or reverse radiation-induced lung fibrosis. Two drugs already approved for idiopathic pulmonary fibrosis, pirfenidone and nintedanib, have been tested in animal models of radiation-induced lung injury. In one preclinical study, an experimental antibody called pamrevlumab outperformed both as a single agent in inhibiting lung remodeling and was the only one to significantly extend survival. Combining nintedanib with pamrevlumab proved even more effective than either alone.28International Journal of Radiation Oncology, Biology, Physics. Comparative Effects of Pamrevlumab, Pirfenidone, and Nintedanib in Experimental Radiation-Induced Lung Fibrosis Meanwhile, researchers have developed human lung organoids, miniature lab-grown lung structures, that can be irradiated and used to screen anti-fibrotic drugs. Pirfenidone successfully suppressed fibrotic markers in these organoids, validating them as a platform for testing new treatments before moving to human trials.29Scientific Reports. A human lung organoid platform for studying radiation-induced pulmonary fibrosis and antifibrotic drug screening None of these therapies are ready for routine clinical use in radiation patients yet, but they represent a shift from simply managing symptoms after the fact to potentially intervening in the fibrotic process itself.